Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SMARTPLUS-106: Debio 1143 in Combination With Nivolumab in Patients Failing Prior PD-1/PD-L1 Treatment
2018-003546-16Phase 2Active
- Sponsor
- Debiopharm
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of xevinapant in Nonhematologic neoplasms and cancer, sponsored by Debiopharm. Started Jan 2019; status: active.
02
Drugs
xevinapant
03
Conditions
Nonhematologic neoplasmscancer
Beyond the preview
Go deeper on 2018-003546-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003546-16.